CLAIMS

1. An implant that fits inside the middle meatus, the implant comprising a coating comprising over 2000 micrograms of mometasone furoate, the implant configured to have a zero-order release for at least 60% of the mometasone furoate.

2. An implant according to Claim 1, in which the implant is configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

3. An implant according to Claim 1, in which the implant is configured to exhibit the zero-order release between 1 and 12 weeks.

4. An implant according to Claim 1, in which the implant is for use in a method of treating a sinus condition.

5. An implant according to Claim 4, in which the sinus condition is chronic.

6. An implant according to Claim 5, in which the sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, loss of smell and facial pain.

7. An implant according to Claim 1, in which the implant comprises up to 5000 micrograms of mometasone furoate.

8. An implant according to Claim 1, in which the implant is a braided structure.

9. An implant according to Claim 1, in which the implant is a tubular structure.

10. An implant according to Claim 1, in which the implant comprises helical strands.

11. An implant according to Claim 1, in which the implant is self-expanding.

12. An implant according to Claim 1, in which the implant has a diameter of at least 13mm.

13. An implant according to Claim 1, in which the implant has a length of at least 10mm.

14. A combination therapy for use in a method of treating a sinus condition, comprising

first and second implants, each comprising at least one coating containing over 2000 micrograms of mometasone furoate,

in which the first implant is configured to fit inside a first middle meatus of a patient, the mometasone furoate configured to have a zero-order release for 12 weeks or more of a planned implantation period; and

in which the second implant is configured to fit inside a second middle meatus of the patient, the mometasone furoate configured to have a zero-order release for 12 weeks or more of a planned implantation period.

15. A therapy according to Claim 14, in which the first and second implants are configured to release 20 to 80% of the mometasone furoate during the first 12 weeks.

16. A therapy according to Claim 14, in which the each of the first and second implants is configured to exhibit a zero-order release after week 1.

17. A therapy according to Claim 14, in which the sinus condition is a chronic sinus condition.

18. A therapy according to Claim 17, in which the sinus condition is characterized by at least two symptoms selected from the group consisting of nasal obstruction, nasal congestion, difficulty breathing through nasal passages, nasal polyp, nasal discharge, loss of smell and facial pain.

19. A therapy according to Claim 14, in which at least one of the first or second implants comprises up to 5000 micrograms of mometasone furoate.

20. A therapy according to Claim 14, in which at least one of the first or second implants is a braided structure.

21. A therapy according to Claim 14, in which at least one of the first or second implants is a tubular structure.

22. A therapy according to Claim 14, in which at least one of the first or second implants comprises helical strands.

23. A therapy according to Claim 14, in which at least one of the first or second implants is self-expanding.